Low-Dose Sorafenib Enhances Chemotherapy Efficacy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Alkylating agents used in chemotherapy cause significant off-target toxicity to healthy tissues, leading to severe side effects and poor prognosis, with a lack of understanding on how normal cells survive alkylation and how to improve cancer treatment efficacy without enhancing toxicity.

Innovation Solution

Administering low-dose Sorafenib in conjunction with chemotherapy to inhibit MAPK pathways, reducing inflammation and angiogenesis while maintaining cell viability, thereby enhancing chemotherapy effectiveness without increasing toxicity to normal tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If alkylating agents are used in chemotherapy, then cancer treatment efficacy is improved, but off-target toxicity to healthy tissues increases

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidoff-target toxicity to healthy tissues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses antioxidants (such as N-acetylcysteine, vitamin C, vitamin E) as intermediary substances that selectively protect healthy tissues from alkylating agent toxicity while allowing cancer cells to be destroyed. These antioxidants act as mediators that scavenge reactive oxygen species and prevent oxidative damage in normal cells, thereby reducing off-target toxicity without compromising the anticancer efficacy of the alkylating agents

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies different qualities to different parts of the system: antioxidants are administered to create a protective environment specifically in healthy tissues, while cancer cells remain vulnerable to alkylating agents. This local differentiation of protective quality allows selective protection of normal cells (liver, kidneys, heart, lungs) while maintaining therapeutic effectiveness against tumors

Inventive Principle:

Principle #3Local quality

2Productivity

If high doses of alkylating agents are administered, then chemotherapy effectiveness is enhanced, but severe side effects and immune suppression worsen

Engineering Contradiction:

Improvechemotherapy effectivenessVSAvoidsevere side effects and immune suppression

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

Antioxidants serve as protective intermediaries that enable the administration of higher doses of alkylating agents by neutralizing the harmful oxidative stress and reactive oxygen species generated during chemotherapy. This mediator approach allows maintaining high therapeutic productivity while the antioxidants continuously protect against the accumulation of harmful effects that would otherwise lead to severe side effects and immune suppression

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent implements beforehand cushioning by pre-administering or co-administering antioxidants before and during alkylating agent therapy. This creates a protective buffer in advance that cushions against the toxic effects of high-dose chemotherapy, preventing severe side effects and immune suppression before they can develop, while still allowing high doses to be administered for maximum cancer cell killing

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Data Source

PatentUS10231958B2Methods and compositions for enhancing chemotherapy

Publication Date: 2019.03.19 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

Embodiments of the invention are directed to methods and compositions using low dose sorafenib to enhance a cancer therapy.